MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

141.08
+2.31
+1.66%
Opening 11:50 06/24 EDT
OPEN
138.21
PREV CLOSE
138.77
HIGH
142.17
LOW
138.21
VOLUME
61.93K
TURNOVER
--
52 WEEK HIGH
183.98
52 WEEK LOW
119.11
MARKET CAP
7.59B
P/E (TTM)
-14.8978
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
Benzinga · 4d ago
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 5d ago
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
Zacks · 06/14 14:41
Wedbush Maintains Outperform on Ascendis Pharma, Lowers Price Target to $189
Wedbush analyst Liana Moussatos maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and lowers the price target from $219 to $189.
Benzinga · 06/14 14:02
Biogen could reach over $600/share: Goldman Sachs, CRISPR upgraded on follow-up data; more in today’s analyst action
goir/iStock via Getty Images Goldman Sachs estimates Biogen to reach above $600 Projecting $28.4B of peak sales for newly-approved Alzheimer’s therapy aducanumab, Goldman Sachs analysts led by Terence Flynn expects
Seekingalpha · 06/14 13:08
FDA extends review period for Ascendis pharma's lonapegsomatropin BLA
Ascendis Pharma (ASND) announced late of Friday that the U.S. FDA has extended the review period for the company's lonapegsomatropin Biologics License Application ((BLA)).The health regulator said that information the
Seekingalpha · 06/14 11:58
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
Benzinga · 06/14 11:23
--Morgan Stanley Adjusts Ascendis Pharma's Price Target to $197 From $201, Maintains Overweight Rating
MT Newswires · 06/14 10:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASND. Analyze the recent business situations of Ascendis Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASND stock price target is 190.59 with a high estimate of 214.60 and a low estimate of 162.93.
EPS
Institutional Holdings
Institutions: 244
Institutional Holdings: 65.85M
% Owned: 122.34%
Shares Outstanding: 53.83M
TypeInstitutionsShares
Increased
80
3.30M
New
23
562.63K
Decreased
52
3.25M
Sold Out
22
185.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.65%
Pharmaceuticals & Medical Research
+1.11%
Key Executives
Chairman/Senior Vice President/General Counsel/Director
Michael Wolff Jensen
Chairman/Senior Vice President/Director
Michael Jensen
President/Chief Executive Officer/Executive Director
Jan Moeller Mikkelsen
President/Chief Executive Officer/Executive Director
Jan Moller Mikkelsen
Chief Financial Officer/Senior Vice President/IR Contact Officer
Scott Smith
Senior Vice President/Chief Administrative Officer
Lotte Soenderbjerg
Senior Vice President
Mark Bach
Senior Vice President
Vibeke Breinholt
Senior Vice President
Jesper Hoiland
Senior Vice President
Flemming Jensen
Senior Vice President
Jens Okkels
Senior Vice President
Dana Pizzuti
Senior Vice President
Juha Punnonen
Senior Vice President
Kennett Sprogoee
Chief Accounting Officer/Vice President - Finance
Peter Rasmussen
Independent Director
Lisa Bright
Independent Director
Albert Cha
Independent Director
James Healy
Independent Director
Lars Holtug
Independent Director
Birgitte Volck
No Data
About ASND
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.

Webull offers kinds of Ascendis Pharma A/S stock information, including NASDAQ:ASND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASND stock methods without spending real money on the virtual paper trading platform.